Navigation Links
FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
Date:10/29/2008

BRIDGEWATER, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) (insulin glulisine [rDNA origin] injection) to improve glycemic control in children (4 years and older) with diabetes mellitus.

The approval of Apidra(R) for pediatric use is based upon FDA review of a 26-week, phase III, open-label, active control study of Apidra(R) in comparison with insulin lispro, in 572 children and adolescents (4 years and older) with type 1 diabetes.

"Sanofi-aventis is committed to providing children with diabetes, as well as their families and healthcare providers, with safe and effective treatment options to help address the challenges associated with the condition and to help decrease the long-term risk for devastating complications of diabetes," said Michelle Baron, MD, vice president, Metabolism Medical Unit, sanofi-aventis U.S. "We are pleased that the fast onset of action and mealtime dosing flexibility of Apidra(R) will now be available to children 4 years and older."

Apidra(R) has a rapid onset and short duration of action and should normally be used in combination with a longer-acting or basal insulin. Apidra(R) can also be used in insulin infusion pump therapy for blood sugar control.

About the Study

The approval of Apidra(R) for pediatric use is based upon a 26-week, phase III, open-label, active control study of Apidra(R) in comparison with insulin lispro in 572 children and adolescents (4 - 17 years of age) with type 1 diabetes. Study patients received insulin glulisine or lispro 0-15 minutes premeal. These patients received concomitant treatment with insulin glargine once daily or NPH twice daily as basal insulin. The majority of the patients received insulin glargine as part of their basal-prandial regimen (69.7% and 72% in the Apidra(R) and insulin lispro treated groups, respectively).

The study compared the efficacy of Apidra(R
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive Intelligence ... and marketplace changes. CI leaders who adjust will succeed, ... In a new Best Practices, LLC study CI leaders ... insights, including: - Use secondary research whenever ... research - Internal staff who are creative ...
(Date:8/29/2014)... Aug. 29, 2014   Mast Therapeutics, Inc. ... announced today that Santosh Vetticaden, Chief Medical Officer ... Company, for personal reasons, in mid-September.  Edwin ... of Aires Pharmaceuticals, which Mast acquired earlier this ... the Company,s interim Chief Medical Officer.  Dr. Parsley ...
(Date:8/29/2014)... 2014 Research and Markets has ... Industry Report, 2014-2017" report to their offering. ... proportion of reimbursement for medical expenses, the Chinese orthopedic ... scale presenting a CAGR of 19.2% during 2009-2013. Trauma ... segments of orthopedic instruments in China ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... Technology, Inc. announced today that Joe Chaudoin and Chris ... Vice President of Sales for the Eastern and Western ... Joe Chaudoin has over 20 years of ... career at Codman and Ethicon-Endo Surgery (both Johnson & ...
... HILLS, Calif., Jan. 19, 2012  HealthTech Capital announced today ... A2 investor in Cadence Biomedical, Inc. The move underscores ... to fund innovative, early-stage companies. Other investors included Alliance ... Angels, and Wings. With a first close of $750,000 ...
Cached Medicine Technology:Zyga Technology, Inc. Makes Two Key Additions to the Sales Leadership Team 2HealthTech Capital Leads Series A2 With Over $300,000 Investment in Cadence Biomedical 2
(Date:8/30/2014)... 2014 Top10BestSEOHosting.com is a well-known ... announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts is the ... Also, they has announced that Bluehost and Arvixe ... Hostgator, one of the Top 10 Web Hosting ... Windows hosting, and it offers rich features and ...
(Date:8/30/2014)... Astoria, New York (PRWEB) August 30, 2014 ... head, back and shoulder pain in our society and ... as lost production costs, it’s vital that continuing education ... with its goal to help physical therapists help others, ... through September 2nd. , Three learning styles ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Jake W., 18, ... while in the Back2Basics Outdoor Adventures transition program ... finish high school so I can actually start on a ... and math, and I'm done.” , He has six months ... Back2Basics program. Most clients choose to continue on to the ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 “In 2013, a ... The Jones Firm says in a recently released article on ... person was injured in an auto accident every 12 minutes, ... minutes,” they continue. “Based on the 2013 statistics, between now ... vehicle collision.” , The threat of an auto accident is ...
(Date:8/30/2014)... 2014 Zensah®, the leader in compression technology ... Sleeve . The camo sleeves are the first released as ... The camo line includes classic colors like army green and ... Known as tibial stress syndrome, shin splints cause dull aches ... Swollen and irritated muscles, stress fractures, or over pronation may ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2
... gloss, depth of image, and surface ... Texas, Oct. 22 Solvay Engineered Polymers,Inc., has ... in the,production of extruded sheet. The new ADDHERE(TM) ... layer onto a substrate of thermoplastic,polyolefin (TPO) for ...
... with Top Children,s Miracle Network Health Experts, SALT LAKE CITY, Oct. 22 /PRNewswire/, ... experts from 170 Children,s ... questions about Methicillin-resistant Staphylococcus Aureus ... to antibiotics, and other ...
... Chairman Howard Dean issued the following statement in response,to ... $46 billion,in war spending, for a total of $196 ... coverage to 10 million of America,s low income children:, ... to fund his war of,choice in Iraq but has ...
... There,s no proof cancer will spread to the ... (HealthDay News) -- Women diagnosed with breast cancer who ... other, healthy breast removed as a preventive measure. , ... mastectomy, more than doubled from 1998 to 2003, according ...
... 22 The start of the,patent lawsuit by VNUS(R) ... laser competitors, Diomed, AngioDynamics and Vascular,Solutions, has been delayed ... delay is due to a busy court calendar. A ... new trial start dates. At,the conference, the parties will ...
... 22 Dialysis Corporation,of America (Nasdaq: DCAI ... third,quarter 2007 earnings after the close of the ... of America owns and operates freestanding kidney,hemodialysis centers ... Carolina and Virginia, and provides in-hospital,dialysis services on ...
Cached Medicine News:Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 2Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 3Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 4Health News:Children's Miracle Network Hospital Doctors On Call to Answer Questions About MRSA Infection 2Health News:More Women Choosing 'Preventive' Double Mastectomy 2Health News:More Women Choosing 'Preventive' Double Mastectomy 3Health News:Delay in Start of VNUS Patent Litigation and Court Ruling on Summary Judgment Motion 2Health News:Dialysis Corporation of America Announces Third Quarter 2007 Earnings Release Date 2
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
...
...
...
Medicine Products: